Alcohol Clinical and Experimental Research,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 19, 2024
Abstract
Background
To
investigate
the
trends
in
alcohol‐associated
liver
disease
(ALD),
cancer
from
alcohol,
and
alcohol
use
disorder
(AUD)
burden
among
older
adults
United
States
(US).
Methods
We
gathered
ALD,
AUD
prevalence,
mortality,
age‐standardized
rates
(ASRs)
Global
Burden
of
Disease
(GBD)
Study
2021
between
2010
2021.
estimated
annual
percent
change
(APC)
with
confidence
intervals
(CIs)
for
(>70
years)
States.
The
findings
were
contrasted
global
estimates
categorized
by
sex
state.
Results
In
2021,
there
approximately
512,340
cases
AUD,
56,990
4490
primary
contrast
to
declining
ASRs
prevalence
mortality
burden,
these
parameters
increased
From
2000
(APC:
0.54%,
95%
CI
0.43%
0.65%),
ALD
(APC
+
0.22%
0.86%),
2.93%,
2.76%
3.11%)
increased.
Forty
states
exhibited
a
rise
adults.
Conclusion
Our
highlighted
Sates,
contrasting
decline
trends.
Public
health
strategies
on
which
targets
adults,
are
urgently
needed.
Liver International,
Год журнала:
2025,
Номер
45(5)
Опубликована: Апрель 3, 2025
ABSTRACT
Metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD)
and
alcohol‐associated
(ALD)
are
the
major
contributors
to
burden
globally.
The
rise
in
these
conditions
is
linked
obesity,
type
2
diabetes,
metabolic
syndrome
increased
alcohol
consumption.
MASLD
ALD
share
risk
factors,
pathophysiology
histological
features
but
differ
their
thresholds
for
use,
definition
does
not
require
presence
of
dysfunction.
A
recent
multi‐society
consensus
overhauled
nomenclature
steatosis
introduced
term
MetALD
describe
patients
with
dysfunction
who
drink
more
than
those
less
ALD.
This
new
terminology
aims
enhance
understanding
management
poses
challenges,
such
as
need
accurately
measure
consumption
research
clinical
practice
settings.
Recent
studies
show
that
has
significant
implications
patient
management,
it
associated
mortality
risks
severe
outcomes
compared
alone.
face
progression,
cancer
cardiovascular
disease.
diagnosis
involves
adequate
quantification
use
through
standardised
questionnaires
and/or
biomarkers
well
proper
assessment
stage
progression
using
non‐invasive
tools
including
serologic
markers,
imaging,
elastography
techniques
genetic
testing.
Effective
requires
addressing
both
alcohol‐related
factors
improve
outcomes.
review
intends
provide
a
comprehensive
overview
MetALD,
covering
pathogenesis,
potential
diagnostic
approaches,
strategies
emerging
therapies.
Hepatology,
Год журнала:
2024,
Номер
80(6), С. 1408 - 1423
Опубликована: Июнь 27, 2024
The
public
health
impact
of
alcohol-associated
liver
disease
(ALD),
a
serious
consequence
problematic
alcohol
use,
and
use
disorder
(AUD)
is
growing,
with
ALD
becoming
major
cause
death
overall
the
leading
indication
for
transplantation
in
United
States.
Comprehensive
care
often
requires
treatment
AUD.
Although
there
growing
body
evidence
showing
that
AUD
associated
reductions
liver-related
morbidity
mortality,
only
minority
patients
receive
this
care.
Integrated
collaborative
models
streamline
both
are
promising
approaches
to
bridge
gap
rely
on
multidisciplinary
interprofessional
teams
partnerships.
Here,
we
review
role
treatment,
effects
outcomes,
comorbid
conditions
such
as
other
substance
disorders,
obesity,
metabolic
syndrome,
current
landscape
integrated
various
settings.
We
further
knowledge
gaps
unmet
needs
remain,
including
precision
medicine,
application
harm
reduction
approaches,
disparities,
need
additional
options,
well
efforts
support
implementation
dissemination.
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 4, 2024
Every
year
millions
die
prematurely
of
complications
related
to
chronic
kidney
disease
(CKD).
Main
causes
death
are
connected
with
cardiovascular
(CV)
complications.
There
is
no
cure
for
CKD
although
current
treatment
can
slow
the
progression
if
diagnosed
early.
Fortunately,
last
decades
have
witnessed
an
accelerating
pace
discovery
regarding
cellular
and
molecular
basis
CV
disease.
Novel
biomarkers,
including
amino-terminal
type
III
procollagen
peptide
(PIIINP),
carboxy-terminal
I
(PICP),
FGF23,
marinobufagenin,
several
miRNAs,
show
promise
early
detection
risk
stratification.
In
this
review,
we
provide
overview
recent
advances
in
"fibrotic
concept"
etiology
pathogenesis
which
involves
system
consisting
Na/K-ATPase
its
endogenous
ligands
marinobufagenin
inhibits
Fli1
stimulates
synthesis
collagen-1
vasculature.
A
novel
already
use
mineralocorticoid
receptor
antagonists
capable
impairing
marinobufagenin-Na/K-ATPase
interactions.
Alcohol Clinical and Experimental Research,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 19, 2024
Abstract
Background
To
investigate
the
trends
in
alcohol‐associated
liver
disease
(ALD),
cancer
from
alcohol,
and
alcohol
use
disorder
(AUD)
burden
among
older
adults
United
States
(US).
Methods
We
gathered
ALD,
AUD
prevalence,
mortality,
age‐standardized
rates
(ASRs)
Global
Burden
of
Disease
(GBD)
Study
2021
between
2010
2021.
estimated
annual
percent
change
(APC)
with
confidence
intervals
(CIs)
for
(>70
years)
States.
The
findings
were
contrasted
global
estimates
categorized
by
sex
state.
Results
In
2021,
there
approximately
512,340
cases
AUD,
56,990
4490
primary
contrast
to
declining
ASRs
prevalence
mortality
burden,
these
parameters
increased
From
2000
(APC:
0.54%,
95%
CI
0.43%
0.65%),
ALD
(APC
+
0.22%
0.86%),
2.93%,
2.76%
3.11%)
increased.
Forty
states
exhibited
a
rise
adults.
Conclusion
Our
highlighted
Sates,
contrasting
decline
trends.
Public
health
strategies
on
which
targets
adults,
are
urgently
needed.
